The number of people in the general population diagnosed with diabetes is expected to dramatically increase in the coming years. Diabetes is a complex, chronic disease that can eventually lead to kidney damage resulting in the need for renal replacement. The diabetic patient approaches dialysis with complications prevalently correlated to an inadequate metabolic control, such as diabetic neuropathy, arterial hypertension, dyslipidaemia and cardiovascular diseases. Dialysis worsens these already present complications both in the acute and chronic phases. The high mortality rate caused by diabetes remains a major concern in dialysis.
Advanced therapies can limit some diabetes-associated complications
The management of diabetes complications in dialysis has been a primary focus for Hospal for many years. Through continuous cooperation with the scientific and medical community, Hospal provides a full range of advanced treatment options – Physio dialysis and AFB™ therapies - aimed at breaking the vicious circle for diabetic patients on dialysis.
Physio dialysis (Hemocontrol and Diacontrol biofeedback systems) may have a beneficial effect on overall diabetes complications during haemodialysis treatment by preventing intra-dialys is hypotension and by managing hypertension. The intrinsic biocompatibility of both AFB™ and AFB.K™ therapies and the AN69ST membrane may allow for a more adequate and effective response to the critical nature of the diabetic patient on HD.